Why 5-MeO-DMT and Ibogaine Should not Be Combined in the Same Retreat
Clinics across Mexico are combining ibogaine and 5-MeO-DMT in short retreats. Sometimes within days of each other. The pitch sounds compelling - two powerful medicines, one trip, maximum results.
The reality is more complicated. And in some cases, dangerous.
We recently brought together four voices with deep experience on both sides of this conversation. Dr. Deborah Mash is a neuroscientist and pharmacologist who conducted the first clinical studies of ibogaine for substance use disorders. Laura Shapiro is the founder of Bassé Ibogaine and has nearly two decades of experience with ibogaine recovery.
Joel Brierre - co-founder of Tandava Retreats and and co-founder of F.I.V.E. Education - has held space for more 5-MeO-DMT sessions than almost anyone in the field. And Victoria Wueschner, co-founder of Tandava and Director of FIVE Education, moderated the discussion. FIVE is the organisation people reach out to when they’ve been harmed or destabilised by a 5-MeO-DMT experience - so this topic is personal.
All four agreed: there is no clinical safety data supporting this combination. None. Each medicine deserves its own container, its own preparation, and its own integration process.
This post breaks down what they shared - and why it matters if you’re considering either medicine.
Why Clinics Are Combining Ibogaine and 5-MeO-DMT
Both ibogaine and 5-MeO-DMT have been around for a long time. Ibogaine has over 150 years of ethnobotanical history. 5-MeO-DMT is present in plant species used in psychoactive snuffs across South America for thousands of years, though its distinct effects weren't identified until the 20th century.
These aren’t new molecules. What’s new is the context.
The psychedelic renaissance has pushed both medicines into clinical trials and mainstream awareness. 5-MeO-DMT received breakthrough therapy designation through Atai/Beckley and is advancing toward FDA approval. The Texas Ibogaine Initiative is building momentum for ibogaine research, driven largely by veterans who’ve gone offshore for help and come back transformed.
With that momentum came a commercial incentive. Clinics - particularly in Mexico - began offering both medicines in the same retreat. Not because clinical research supported the combination. Because demand was there and nobody was saying no.
As Dr. Mash put it during our panel: there are no clinical data sets that inform the safety of this combination. No therapeutic protocols were developed. No adverse events were tracked. Somewhere along the way, it just became standard practice at certain centres.
Joel flagged something even more concerning. Some clinics appear to be low-dosing ibogaine - because proper dosing requires serious cardiac monitoring - and then adding 5-MeO-DMT at the end to give participants a sense that “something happened.” Laura Shapiro confirmed she’s hearing the same thing from clients calling Bassé.
That’s not a protocol. It’s a workaround. And it puts participants at risk for the sake of a satisfying exit experience rather than lasting change.
What Happens in Your Brain When You Combine Two Powerful Psychedelics
The reason this combination is risky isn’t philosophical. It’s neurological.
Both ibogaine and 5-MeO-DMT open windows of neuroplasticity in the brain. That’s part of what makes each medicine so effective on its own. But they do it in very different ways - and stacking one on top of the other while the brain is still mid-reset is uncharted territory.
Ibogaine works slowly. The experience lasts 18–36 hours. It produces a long, introspective, narrative journey - Laura Shapiro describes it as a 3,000-foot aerial view of your entire life.
After the experience, ibogaine is metabolised into noribogaine, an active metabolite that stays in your system for days or even weeks. Noribogaine elevates serotonin levels and is believed to be a key driver of ibogaine’s lasting effects.
5-MeO-DMT works fast. The peak experience lasts around 20 minutes. It’s immersive, not visual. Many participants describe ego dissolution - a temporary loss of the sense of self, time, and space.
Recent EEG research in collaboration with Tandava has shown that 5-MeO-DMT disrupts normal oscillatory patterns in the brain in ways that are still being studied. The experience may not even be remembered. But it opens a doorway to deep subconscious content that can surface for weeks afterward.
Here’s the problem. Researchers at Johns Hopkins and UC Berkeley have shown that psychedelics reopen a critical learning period in the brain - a window where neural connections are unusually plastic and responsive. We don’t know how long that window stays open. According to Dr. Mash, it could be far longer than most people assume.
Now picture this: a participant does ibogaine. Their brain enters a state of deep neurochemical reorganisation. Noribogaine is still active, elevating serotonin. The plasticity window is wide open.
And within 24–48 hours, they inhale 5-MeO-DMT - a compound that also acts on serotonin receptors and sends a completely different kind of disruption through an already destabilised system.
What happens next? Dr. Mash was blunt: we don’t know. We don’t know if the effects are additive. We don’t know if they’re synergistic.
We don’t know if 5-MeO-DMT erases the progress made during ibogaine, or amplifies it, or scrambles it entirely. And we don’t know if some participants are being put at risk for serotonin syndrome - a potentially life-threatening condition caused by excessive serotonin activity.
Nobody has designed a study to answer these questions. The few publications that exist on the combination don’t report adverse events. As Dr. Mash put it: those data were simply not collected.
Why a 5-Day Retreat Isn’t Long Enough for Both Medicines
Even if the pharmacology wasn’t a concern - and it is - the logistics alone should raise questions.
At Bassé, Laura Shapiro’s team never administers ibogaine before day four. The first three days are medical preparation: daily EKGs, a full liver panel, blood work, electrolyte balancing, urine drug screens, and psychological evaluation.
Ibogaine has a narrow therapeutic window. It affects the cardiovascular system directly. QT prolongation - a disruption to the heart’s electrical cycle - is a known and manageable risk, but only if qualified clinicians are monitoring it. You don’t cut corners with that.
After ibogaine, participants need rest. Laura describes the post-ibogaine period as a time for lavender tea, turbine baths, somatic work, and sleep. The nervous system has been cracked open. It needs nurturing, not another powerful compound.
At Tandava, a 5-MeO-DMT retreat runs a minimum of five days. That’s with two weeks of individual preparation before arrival and four weeks of one-on-one integration afterward. The retreat itself includes private ceremony sessions, titrated dosing, and on-site integration.
Joel has been clear that even for 5-MeO-DMT alone, five days is the floor, not the ceiling.
So consider what some clinics are doing: ibogaine and 5-MeO-DMT in a four-to-six day window. Participants arrive, receive ibogaine within a day or two, and sit with 5-MeO-DMT the day before they leave. Some are put on a plane the morning after.
Victoria Wueschner was direct about what FIVE has been seeing: participants arriving at these clinics without even knowing 5-MeO-DMT was part of the programme. It becomes peer pressure. People pay extra for it.
There’s no separate intention set for it. No dedicated preparation. And certainly no dedicated integration.
Joel put it plainly: 5-MeO-DMT may be getting used to give a little extra bang. So people leave feeling like something happened - rather than relying on the harder, slower work of skilled integration specialists to process what ibogaine already opened up.
That’s an experience designed around a satisfying departure, not lasting change.
The Reports Coming in from People Who’ve Done Both
FIVE Education is the organisation people contact when a 5-MeO-DMT experience goes wrong. It’s been that way for years. The team fields adverse experience reports from around the world - it comes with the territory of being the largest educational resource in the 5-MeO-DMT space.
Over the past year, something shifted. The volume of reports increased. And a pattern emerged.
People were reaching out in crisis after visiting popular ibogaine clinics that added 5-MeO-DMT to their programmes. The stories carried a consistent thread: they weren’t prepared for the 5-MeO-DMT. They didn’t know what it would be like. It was treated as a little extra - an add-on at the end of an already intense ibogaine experience.
Some struggled with sleep. Others couldn’t regulate their mood. Several described a fractured sense of identity - not knowing who they were when they got home.
A few didn’t hit crisis until three or four weeks later, which is actually a normal timeline for 5-MeO-DMT content to surface. But without integration support, they had no framework to understand what was happening to them.
One story from the webinar audience captured the pattern clearly. A participant received both ibogaine and 5-MeO-DMT and was put on a plane the following day.
When they returned home, they were open and sensitive. Sleep was disrupted. Mood was swinging. Their sense of self felt unstable. They felt a strong pull to go back - and a growing conviction that they’d done it wrong.
That last part is the most telling. When someone walks away from a psychedelic experience believing they failed, it usually means they weren’t informed about the process-oriented nature of the work.
Difficult integration isn’t failure. It’s the work itself. But without anyone explaining that - without preparation, without aftercare, without a specialist who understands the specific landscape of 5-MeO-DMT - participants are left to interpret their experience alone. And many conclude they’re broken.
Dr. Mash shared her own case. A young woman who had been on antidepressants for years decided to come off them and went to a prominent ibogaine clinic offering the combination. She felt well for a few weeks after returning home.
Then a rebound hit - severe enough that she hospitalised herself. Dr. Mash described the rebound as unlike anything she’d seen with ibogaine alone.
One case is an anecdote. Dr. Mash said that clearly. But she also said this: the reason all four panellists took the time to have this conversation publicly is because these stories aren’t isolated anymore. They’re accelerating.
Not everyone who does the combination is harmed. Some people report positive outcomes. But the rate of adverse reports is climbing - and the people fielding those reports are the same people on this panel.
Why Each Medicine Deserves Its Own Space
This isn’t an argument against either medicine. It’s an argument against rushing them.
Ibogaine and 5-MeO-DMT are both profound. They’re also fundamentally different experiences that require fundamentally different support.
Ibogaine takes you on a long, narrative journey. Laura describes it as a deep reset - re-parenting the nervous system. Participants often get a full-life review. They see how and why things unfolded the way they did.
The experience can last overnight. And when it’s over, the body and psyche need gentleness. Rest. Somatic work. Time to let the insights settle before trying to make sense of them.
The active metabolite, noribogaine, is still working in the background for days or weeks. The healing hasn’t stopped just because the visions have.
5-MeO-DMT is a different animal entirely. The peak lasts around 20 minutes. It’s not narrative. It’s not visual in the way most people expect psychedelics to be. Many participants can’t remember the experience at all.
What they can tell you is that something shifted - something deep. Content from childhood, from decades ago, can begin surfacing days or weeks later with no warning. And without a skilled integration specialist who understands the specific terrain of 5-MeO-DMT, that content can become overwhelming fast.
The integration needs aren’t just different in degree. They’re different in kind.
An ibogaine integration specialist may have deep experience supporting people through narrative, memory-based processing. But 5-MeO-DMT doesn’t give you a narrative. It gives you an opening - and what comes through that opening requires a different skill set to hold.
Joel made the point clearly: the idea that someone would have the understanding and skill to safely hold space for both medicines simultaneously is ambitious at best. Nobody has had enough time to master both.
Laura Shapiro recommends at least three months between ibogaine and any other psychedelic work. Not as an arbitrary number - but because the noribogaine is still active, the plasticity window is still open, and the nervous system needs space to integrate what it’s already been given.
If someone wants to work with both medicines, the responsible path looks like this: do one. Give it its own preparation. Give it its own container. Give it months of integration.
Then - if and when the time is right - approach the second medicine with the same intention and care. Set new goals. Work with a team that specialises in that specific medicine. Treat it as its own journey, not a sequel.
Laura put it simply during the panel: more is not more. True healing requires slowness, attention, and the space to actually come home to yourself.
What to Look for Before You Book a Retreat
If you’re considering ibogaine or 5-MeO-DMT, the single most important thing you can do is ask questions. The right centre will welcome them. The wrong one will rush past them.
For ibogaine, Laura and Dr. Mash outlined clear markers of a responsible programme:
Medical screening should happen before you’re accepted - not after you arrive. That means a full review of your health history, current medications, and any pre-existing conditions. Ibogaine interacts with certain medications and is metabolised through a liver enzyme that varies genetically.
If nobody asks what you’re taking, that’s a problem.
On-site medical care should be 24/7 during and after dosing. Daily EKGs. A full liver panel and blood work. Electrolyte monitoring. Staff should be ACLS-certified and trained in cardiac monitoring - not just present, but qualified to read what they’re seeing.
Dr. Mash was clear: if a centre offers to dose you on day one without any of this, take your suitcase and leave.
Laura added that ibogaine is not a retreat in the traditional sense. It’s a procedure that requires a medical setting. Any centre calling itself an “ibogaine retreat” without proper clinical infrastructure should raise questions.
For 5-MeO-DMT, Joel outlined what Tandava looks for - and what participants should expect from any responsible centre:
Preparation should be individual and begin weeks before arrival. Not a group briefing on the morning of the ceremony. The facilitator should understand your history, your goals, and your psychological landscape before you sit with the medicine.
Dosing should be individually attuned. At Tandava, each participant's dosage protocol and route of administration is based on their unique process and what is coming up in real time. This often involves titrating up in what is known as the "handshake, hug, full release" protocol.
Cookie-cutter dosing is a red flag. So is any centre that jumps straight to a high dose without building up gradually.
Integration should be mandatory, not optional. If a centre says “we’re here if you need us” rather than building aftercare into the programme, that tells you something.
5-MeO-DMT can surface deep subconscious content for weeks after the experience. Without a specialist who understands that specific terrain, participants are left to process it alone - and that’s where things go sideways.
It’s also worth asking what form of 5-MeO-DMT a centre uses. At Tandava, we work with synthetic 5-MeO-DMT - not toad-derived (Bufo Alvarius). Synthetic ensures dosage accuracy, consistency between sessions, and protects the natural toad population. Any centre that can’t tell you the source and purity of what they’re offering is another red flag.
On-site medical staff is important for 5-MeO-DMT too. The cardiac risk is lower than ibogaine, but there is a temporary spike to blood pressure and heart rate. More critically, the intensity of the experience can produce presentations that look like emergencies to untrained eyes.
A qualified team knows the difference between catharsis and crisis.
For any centre offering either medicine, watch for these red flags: no preparation or screening process. Medicines combined in the same short retreat. No dedicated integration programme. Pressure to add on extra substances.
Staff who can’t clearly explain their protocols, their training, or their emergency procedures.
Dr. Mash’s advice was simple: ask a lot of questions. Meet the clinicians. Read the informed consent. And if something doesn’t feel right, trust that instinct.
Why This Matters for the Future of Psychedelic Medicine
This isn’t just about individual safety. It’s about what happens to the entire field when things go wrong.
Both ibogaine and 5-MeO-DMT are closer to regulatory approval than they’ve ever been. Atai/Beckley has breakthrough therapy designation for 5-MeO-DMT and is moving toward phase three trials for treatment-resistant depression. GH Research is on a similar path.
Joel’s own company, FIVE Discovery, is developing non-hallucinogenic analogs of 5-MeO-DMT for brain health and CNS disorders. On the ibogaine side, Sonera is advancing clinical trials, and the Texas Ibogaine Initiative is building political and institutional support.
These are real regulatory pathways. Years of work. And they can be derailed by a single high-profile adverse event at a clinic cutting corners.
Dr. Mash made this point sharply. When someone has a bad outcome after receiving both ibogaine and 5-MeO-DMT, who gets the blame? Was it the ibogaine? The 5-MeO-DMT? The interaction? The lack of screening?
Nobody knows - because the combination was never studied. But the adverse event still gets reported. It goes to poison control centres. It reaches the FDA. And it becomes ammunition for anyone who wants to slow down or shut down the approval process for either medicine.
Every irresponsible centre that combines these medicines without data, without protocols, and without proper aftercare is putting the broader movement at risk. Not in theory. In practice.
The people who will pay the price aren’t the clinic operators. It’s the millions of people waiting for legal, regulated access to medicines that could change their lives.
Veterans with PTSD who can’t access ibogaine domestically. People with treatment-resistant depression who’ve exhausted every approved option. They’re the ones who lose when the field gets set back.
Dr. Mash put it plainly: every time one of these centres does something wrong, it puts the genie back in the bottle.
Two Powerful Medicines. Two Separate Journeys.
Ibogaine and 5-MeO-DMT are both capable of profound change. That’s not in dispute. The research is promising. The lived experiences are real.
And both medicines are moving toward a future where more people will have safe, legal access to them.
But powerful doesn’t mean interchangeable. And more doesn’t mean better.
Each of these medicines works differently in the brain, produces a different kind of experience, and requires a different kind of support before, during, and after. Compressing both into a single short retreat - without clinical data, without dedicated preparation for each, and without specialised integration - isn’t bold or innovative. It’s careless.
If you’re considering ibogaine for addiction recovery or deep emotional processing, find a centre that treats it as the serious procedure it is. Laura Shapiro and Dr. Mash have spent decades building the safety standards that responsible ibogaine work demands. Bassé Ibogaine is a good place to start that conversation.
If you’re drawn to 5-MeO-DMT for healing, growth, or personal transformation, look for a programme that gives the medicine the space it deserves. Weeks of preparation. Private ceremony sessions with titrated dosing. A month of dedicated integration afterward.
That’s what the work actually looks like. Book a discovery call with Tandava to learn more about our approach.
And if you want to work with both? Give each one its own time. Its own container. Its own team. Space them months apart. Let the first one do its work before you reach for the second.
These medicines have the potential to help a lot of people. Let’s not waste that potential by rushing.
Clinics across Mexico are combining ibogaine and 5-MeO-DMT in short retreats. Sometimes within days of each other. The pitch sounds compelling - two powerful medicines, one trip, maximum results.
The reality is more complicated. And in some cases, dangerous.
We recently brought together four voices with deep experience on both sides of this conversation. Dr. Deborah Mash is a neuroscientist and pharmacologist who conducted the first clinical studies of ibogaine for substance use disorders. Laura Shapiro is the founder of Bassé Ibogaine and has nearly two decades of experience with ibogaine recovery.
Joel Brierre - co-founder of Tandava Retreats and and co-founder of F.I.V.E. Education - has held space for more 5-MeO-DMT sessions than almost anyone in the field. And Victoria Wueschner, co-founder of Tandava and Director of FIVE Education, moderated the discussion. FIVE is the organisation people reach out to when they’ve been harmed or destabilised by a 5-MeO-DMT experience - so this topic is personal.
All four agreed: there is no clinical safety data supporting this combination. None. Each medicine deserves its own container, its own preparation, and its own integration process.
This post breaks down what they shared - and why it matters if you’re considering either medicine.
Why Clinics Are Combining Ibogaine and 5-MeO-DMT
Both ibogaine and 5-MeO-DMT have been around for a long time. Ibogaine has over 150 years of ethnobotanical history. 5-MeO-DMT is present in plant species used in psychoactive snuffs across South America for thousands of years, though its distinct effects weren't identified until the 20th century.
These aren’t new molecules. What’s new is the context.
The psychedelic renaissance has pushed both medicines into clinical trials and mainstream awareness. 5-MeO-DMT received breakthrough therapy designation through Atai/Beckley and is advancing toward FDA approval. The Texas Ibogaine Initiative is building momentum for ibogaine research, driven largely by veterans who’ve gone offshore for help and come back transformed.
With that momentum came a commercial incentive. Clinics - particularly in Mexico - began offering both medicines in the same retreat. Not because clinical research supported the combination. Because demand was there and nobody was saying no.
As Dr. Mash put it during our panel: there are no clinical data sets that inform the safety of this combination. No therapeutic protocols were developed. No adverse events were tracked. Somewhere along the way, it just became standard practice at certain centres.
Joel flagged something even more concerning. Some clinics appear to be low-dosing ibogaine - because proper dosing requires serious cardiac monitoring - and then adding 5-MeO-DMT at the end to give participants a sense that “something happened.” Laura Shapiro confirmed she’s hearing the same thing from clients calling Bassé.
That’s not a protocol. It’s a workaround. And it puts participants at risk for the sake of a satisfying exit experience rather than lasting change.
What Happens in Your Brain When You Combine Two Powerful Psychedelics
The reason this combination is risky isn’t philosophical. It’s neurological.
Both ibogaine and 5-MeO-DMT open windows of neuroplasticity in the brain. That’s part of what makes each medicine so effective on its own. But they do it in very different ways - and stacking one on top of the other while the brain is still mid-reset is uncharted territory.
Ibogaine works slowly. The experience lasts 18–36 hours. It produces a long, introspective, narrative journey - Laura Shapiro describes it as a 3,000-foot aerial view of your entire life.
After the experience, ibogaine is metabolised into noribogaine, an active metabolite that stays in your system for days or even weeks. Noribogaine elevates serotonin levels and is believed to be a key driver of ibogaine’s lasting effects.
5-MeO-DMT works fast. The peak experience lasts around 20 minutes. It’s immersive, not visual. Many participants describe ego dissolution - a temporary loss of the sense of self, time, and space.
Recent EEG research in collaboration with Tandava has shown that 5-MeO-DMT disrupts normal oscillatory patterns in the brain in ways that are still being studied. The experience may not even be remembered. But it opens a doorway to deep subconscious content that can surface for weeks afterward.
Here’s the problem. Researchers at Johns Hopkins and UC Berkeley have shown that psychedelics reopen a critical learning period in the brain - a window where neural connections are unusually plastic and responsive. We don’t know how long that window stays open. According to Dr. Mash, it could be far longer than most people assume.
Now picture this: a participant does ibogaine. Their brain enters a state of deep neurochemical reorganisation. Noribogaine is still active, elevating serotonin. The plasticity window is wide open.
And within 24–48 hours, they inhale 5-MeO-DMT - a compound that also acts on serotonin receptors and sends a completely different kind of disruption through an already destabilised system.
What happens next? Dr. Mash was blunt: we don’t know. We don’t know if the effects are additive. We don’t know if they’re synergistic.
We don’t know if 5-MeO-DMT erases the progress made during ibogaine, or amplifies it, or scrambles it entirely. And we don’t know if some participants are being put at risk for serotonin syndrome - a potentially life-threatening condition caused by excessive serotonin activity.
Nobody has designed a study to answer these questions. The few publications that exist on the combination don’t report adverse events. As Dr. Mash put it: those data were simply not collected.
Why a 5-Day Retreat Isn’t Long Enough for Both Medicines
Even if the pharmacology wasn’t a concern - and it is - the logistics alone should raise questions.
At Bassé, Laura Shapiro’s team never administers ibogaine before day four. The first three days are medical preparation: daily EKGs, a full liver panel, blood work, electrolyte balancing, urine drug screens, and psychological evaluation.
Ibogaine has a narrow therapeutic window. It affects the cardiovascular system directly. QT prolongation - a disruption to the heart’s electrical cycle - is a known and manageable risk, but only if qualified clinicians are monitoring it. You don’t cut corners with that.
After ibogaine, participants need rest. Laura describes the post-ibogaine period as a time for lavender tea, turbine baths, somatic work, and sleep. The nervous system has been cracked open. It needs nurturing, not another powerful compound.
At Tandava, a 5-MeO-DMT retreat runs a minimum of five days. That’s with two weeks of individual preparation before arrival and four weeks of one-on-one integration afterward. The retreat itself includes private ceremony sessions, titrated dosing, and on-site integration.
Joel has been clear that even for 5-MeO-DMT alone, five days is the floor, not the ceiling.
So consider what some clinics are doing: ibogaine and 5-MeO-DMT in a four-to-six day window. Participants arrive, receive ibogaine within a day or two, and sit with 5-MeO-DMT the day before they leave. Some are put on a plane the morning after.
Victoria Wueschner was direct about what FIVE has been seeing: participants arriving at these clinics without even knowing 5-MeO-DMT was part of the programme. It becomes peer pressure. People pay extra for it.
There’s no separate intention set for it. No dedicated preparation. And certainly no dedicated integration.
Joel put it plainly: 5-MeO-DMT may be getting used to give a little extra bang. So people leave feeling like something happened - rather than relying on the harder, slower work of skilled integration specialists to process what ibogaine already opened up.
That’s an experience designed around a satisfying departure, not lasting change.
The Reports Coming in from People Who’ve Done Both
FIVE Education is the organisation people contact when a 5-MeO-DMT experience goes wrong. It’s been that way for years. The team fields adverse experience reports from around the world - it comes with the territory of being the largest educational resource in the 5-MeO-DMT space.
Over the past year, something shifted. The volume of reports increased. And a pattern emerged.
People were reaching out in crisis after visiting popular ibogaine clinics that added 5-MeO-DMT to their programmes. The stories carried a consistent thread: they weren’t prepared for the 5-MeO-DMT. They didn’t know what it would be like. It was treated as a little extra - an add-on at the end of an already intense ibogaine experience.
Some struggled with sleep. Others couldn’t regulate their mood. Several described a fractured sense of identity - not knowing who they were when they got home.
A few didn’t hit crisis until three or four weeks later, which is actually a normal timeline for 5-MeO-DMT content to surface. But without integration support, they had no framework to understand what was happening to them.
One story from the webinar audience captured the pattern clearly. A participant received both ibogaine and 5-MeO-DMT and was put on a plane the following day.
When they returned home, they were open and sensitive. Sleep was disrupted. Mood was swinging. Their sense of self felt unstable. They felt a strong pull to go back - and a growing conviction that they’d done it wrong.
That last part is the most telling. When someone walks away from a psychedelic experience believing they failed, it usually means they weren’t informed about the process-oriented nature of the work.
Difficult integration isn’t failure. It’s the work itself. But without anyone explaining that - without preparation, without aftercare, without a specialist who understands the specific landscape of 5-MeO-DMT - participants are left to interpret their experience alone. And many conclude they’re broken.
Dr. Mash shared her own case. A young woman who had been on antidepressants for years decided to come off them and went to a prominent ibogaine clinic offering the combination. She felt well for a few weeks after returning home.
Then a rebound hit - severe enough that she hospitalised herself. Dr. Mash described the rebound as unlike anything she’d seen with ibogaine alone.
One case is an anecdote. Dr. Mash said that clearly. But she also said this: the reason all four panellists took the time to have this conversation publicly is because these stories aren’t isolated anymore. They’re accelerating.
Not everyone who does the combination is harmed. Some people report positive outcomes. But the rate of adverse reports is climbing - and the people fielding those reports are the same people on this panel.
Why Each Medicine Deserves Its Own Space
This isn’t an argument against either medicine. It’s an argument against rushing them.
Ibogaine and 5-MeO-DMT are both profound. They’re also fundamentally different experiences that require fundamentally different support.
Ibogaine takes you on a long, narrative journey. Laura describes it as a deep reset - re-parenting the nervous system. Participants often get a full-life review. They see how and why things unfolded the way they did.
The experience can last overnight. And when it’s over, the body and psyche need gentleness. Rest. Somatic work. Time to let the insights settle before trying to make sense of them.
The active metabolite, noribogaine, is still working in the background for days or weeks. The healing hasn’t stopped just because the visions have.
5-MeO-DMT is a different animal entirely. The peak lasts around 20 minutes. It’s not narrative. It’s not visual in the way most people expect psychedelics to be. Many participants can’t remember the experience at all.
What they can tell you is that something shifted - something deep. Content from childhood, from decades ago, can begin surfacing days or weeks later with no warning. And without a skilled integration specialist who understands the specific terrain of 5-MeO-DMT, that content can become overwhelming fast.
The integration needs aren’t just different in degree. They’re different in kind.
An ibogaine integration specialist may have deep experience supporting people through narrative, memory-based processing. But 5-MeO-DMT doesn’t give you a narrative. It gives you an opening - and what comes through that opening requires a different skill set to hold.
Joel made the point clearly: the idea that someone would have the understanding and skill to safely hold space for both medicines simultaneously is ambitious at best. Nobody has had enough time to master both.
Laura Shapiro recommends at least three months between ibogaine and any other psychedelic work. Not as an arbitrary number - but because the noribogaine is still active, the plasticity window is still open, and the nervous system needs space to integrate what it’s already been given.
If someone wants to work with both medicines, the responsible path looks like this: do one. Give it its own preparation. Give it its own container. Give it months of integration.
Then - if and when the time is right - approach the second medicine with the same intention and care. Set new goals. Work with a team that specialises in that specific medicine. Treat it as its own journey, not a sequel.
Laura put it simply during the panel: more is not more. True healing requires slowness, attention, and the space to actually come home to yourself.
What to Look for Before You Book a Retreat
If you’re considering ibogaine or 5-MeO-DMT, the single most important thing you can do is ask questions. The right centre will welcome them. The wrong one will rush past them.
For ibogaine, Laura and Dr. Mash outlined clear markers of a responsible programme:
Medical screening should happen before you’re accepted - not after you arrive. That means a full review of your health history, current medications, and any pre-existing conditions. Ibogaine interacts with certain medications and is metabolised through a liver enzyme that varies genetically.
If nobody asks what you’re taking, that’s a problem.
On-site medical care should be 24/7 during and after dosing. Daily EKGs. A full liver panel and blood work. Electrolyte monitoring. Staff should be ACLS-certified and trained in cardiac monitoring - not just present, but qualified to read what they’re seeing.
Dr. Mash was clear: if a centre offers to dose you on day one without any of this, take your suitcase and leave.
Laura added that ibogaine is not a retreat in the traditional sense. It’s a procedure that requires a medical setting. Any centre calling itself an “ibogaine retreat” without proper clinical infrastructure should raise questions.
For 5-MeO-DMT, Joel outlined what Tandava looks for - and what participants should expect from any responsible centre:
Preparation should be individual and begin weeks before arrival. Not a group briefing on the morning of the ceremony. The facilitator should understand your history, your goals, and your psychological landscape before you sit with the medicine.
Dosing should be individually attuned. At Tandava, each participant's dosage protocol and route of administration is based on their unique process and what is coming up in real time. This often involves titrating up in what is known as the "handshake, hug, full release" protocol.
Cookie-cutter dosing is a red flag. So is any centre that jumps straight to a high dose without building up gradually.
Integration should be mandatory, not optional. If a centre says “we’re here if you need us” rather than building aftercare into the programme, that tells you something.
5-MeO-DMT can surface deep subconscious content for weeks after the experience. Without a specialist who understands that specific terrain, participants are left to process it alone - and that’s where things go sideways.
It’s also worth asking what form of 5-MeO-DMT a centre uses. At Tandava, we work with synthetic 5-MeO-DMT - not toad-derived (Bufo Alvarius). Synthetic ensures dosage accuracy, consistency between sessions, and protects the natural toad population. Any centre that can’t tell you the source and purity of what they’re offering is another red flag.
On-site medical staff is important for 5-MeO-DMT too. The cardiac risk is lower than ibogaine, but there is a temporary spike to blood pressure and heart rate. More critically, the intensity of the experience can produce presentations that look like emergencies to untrained eyes.
A qualified team knows the difference between catharsis and crisis.
For any centre offering either medicine, watch for these red flags: no preparation or screening process. Medicines combined in the same short retreat. No dedicated integration programme. Pressure to add on extra substances.
Staff who can’t clearly explain their protocols, their training, or their emergency procedures.
Dr. Mash’s advice was simple: ask a lot of questions. Meet the clinicians. Read the informed consent. And if something doesn’t feel right, trust that instinct.
Why This Matters for the Future of Psychedelic Medicine
This isn’t just about individual safety. It’s about what happens to the entire field when things go wrong.
Both ibogaine and 5-MeO-DMT are closer to regulatory approval than they’ve ever been. Atai/Beckley has breakthrough therapy designation for 5-MeO-DMT and is moving toward phase three trials for treatment-resistant depression. GH Research is on a similar path.
Joel’s own company, FIVE Discovery, is developing non-hallucinogenic analogs of 5-MeO-DMT for brain health and CNS disorders. On the ibogaine side, Sonera is advancing clinical trials, and the Texas Ibogaine Initiative is building political and institutional support.
These are real regulatory pathways. Years of work. And they can be derailed by a single high-profile adverse event at a clinic cutting corners.
Dr. Mash made this point sharply. When someone has a bad outcome after receiving both ibogaine and 5-MeO-DMT, who gets the blame? Was it the ibogaine? The 5-MeO-DMT? The interaction? The lack of screening?
Nobody knows - because the combination was never studied. But the adverse event still gets reported. It goes to poison control centres. It reaches the FDA. And it becomes ammunition for anyone who wants to slow down or shut down the approval process for either medicine.
Every irresponsible centre that combines these medicines without data, without protocols, and without proper aftercare is putting the broader movement at risk. Not in theory. In practice.
The people who will pay the price aren’t the clinic operators. It’s the millions of people waiting for legal, regulated access to medicines that could change their lives.
Veterans with PTSD who can’t access ibogaine domestically. People with treatment-resistant depression who’ve exhausted every approved option. They’re the ones who lose when the field gets set back.
Dr. Mash put it plainly: every time one of these centres does something wrong, it puts the genie back in the bottle.
Two Powerful Medicines. Two Separate Journeys.
Ibogaine and 5-MeO-DMT are both capable of profound change. That’s not in dispute. The research is promising. The lived experiences are real.
And both medicines are moving toward a future where more people will have safe, legal access to them.
But powerful doesn’t mean interchangeable. And more doesn’t mean better.
Each of these medicines works differently in the brain, produces a different kind of experience, and requires a different kind of support before, during, and after. Compressing both into a single short retreat - without clinical data, without dedicated preparation for each, and without specialised integration - isn’t bold or innovative. It’s careless.
If you’re considering ibogaine for addiction recovery or deep emotional processing, find a centre that treats it as the serious procedure it is. Laura Shapiro and Dr. Mash have spent decades building the safety standards that responsible ibogaine work demands. Bassé Ibogaine is a good place to start that conversation.
If you’re drawn to 5-MeO-DMT for healing, growth, or personal transformation, look for a programme that gives the medicine the space it deserves. Weeks of preparation. Private ceremony sessions with titrated dosing. A month of dedicated integration afterward.
That’s what the work actually looks like. Book a discovery call with Tandava to learn more about our approach.
And if you want to work with both? Give each one its own time. Its own container. Its own team. Space them months apart. Let the first one do its work before you reach for the second.
These medicines have the potential to help a lot of people. Let’s not waste that potential by rushing.